BRVE
Braveheart Bio, Inc.
$20.62
-2.75
(-11.77%)
Mkt Cap
1.65B
Volume
471,827
52W Range
20.695-32
Sector
Healthcare
Beta
0.00
EPS (TTM)
N/A
P/E Ratio
N/A
Revenue (TTM)
N/A
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
BRVE News
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio to Participate in Cantor Global Healthcare Conference
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
Braveheart Bio (NASDAQ:BRVE) Director Purchases $999,990.00 in Stock
Braveheart Bio (NASDAQ:BRVE) CFO Buys $499,986.00 in Stock
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Braveheart Bio Announces Pricing of Upsized Initial Public Offering